Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS ...

A key pillar of the Saudi National Culture Strategy, aligned with Vision 2030, was the focus of a new Market Outlook Report launched by global research and advisory firm Oxford Business Group (OBG) in ...